# US 2022/0034888 A1 · Use of circulating tumor cell mitotic index in cancer stratification and diagnostics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0034888 A1
- Document ID: US20220034888A1
- Status: Published application
- Kind: A1
- Application number: 17/503,872
- Filed: 2021-10-18
- Published: 2022-02-03
- Earliest claimed: 2015-05-26
- Assignees: Creatv MicroTech, Inc.
- Applicants: Creatv Microtech Inc.
- Inventors: Daniel ADAMS; Cha-Mei TANG
- Web page: https://patentgrep.com/patent/US20220034888A1

## CPC

- G01N 33/575: for cancer
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/5751: of the skin, e.g. melanoma
- G01N 33/57515: of the breast
- G01N 33/5752: of the lungs
- G01N 33/57525: of the liver or pancreas
- G01N 33/5753: of the stomach or small intestine
- G01N 33/57555: of the prostate
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N 2800/7028: Cancer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Circulating tumor cells (CTCs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that CTCs exhibit cell cycle phase variability and that there is a strong correlation between the number of CTCs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained. Also presented herein are methods of determining the mitotic cell cycle phase of CTCs from a patient having cancer and using the information in grading malignant solid tumors and predicting the likelihood of survival of the patient.

## Claims

### Claim 1

A method for monitoring the effectiveness of treatment in a subject having cancer, wherein the method comprises:
(a) obtaining a first population of CTCs from a first biological sample of a subject having cancer,
(b) screening the first population for cells in a mitotic cell cycle phase,
(c) administering a cancer treatment to the subject,
(d) obtaining a second population of CTCs from a second biological sample of the subject after treatment, and
(e) screening the second population for cells in a mitotic cell cycle phase,
wherein an increase in the number of mitotic CTCs in the second population versus the first population, or an increase in the mitotic index calculated for the second population versus the first population, suggests the treatment is ineffective.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biological sample is selected from the group consisting of peripheral blood, blood, lymph nodes, bone marrow, cerebral spinal fluid, and urine, and wherein the first and second biological samples are from the same source.

### Claim 3 (depends on 2)

The method of claim 2, wherein the first and second biological samples are at least about 7.5 mL of peripheral blood.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer is carcinoma and the CTCs are characterized by one or more of the following characteristics:
(a) diameter of between about 7 and 25 microns,
(b) presence of one or more markers selected from the group consisting of cytokeratin (CK) 8, CK18, CK19, and EpCAM, and
(c) absence of one or more markers selected from the group consisting of CD45, CD14, and CD31.

### Claim 5 (depends on 4)

The method of claim 4, wherein the CTCs are further characterized by presence of one or more markers selected from the group consisting of EGFR, HER2, MUC-1, EphB4, CEA, CK5, CK6, CK7, CK14, CK16, CK17, CK20, PLZ4, PSMA, PSA, PDX-1, CXCR-4, and CDX2.

### Claim 6 (depends on 4)

The method of claim 4, wherein carcinoma is a breast, prostate, lung, colorectal or pancreatic tumor, and wherein CTCs are characterized by the following characteristics:
(a) diameter of between about 7 and 25 microns,
(b) presence of CK8, CK18, CK19, and EpCAM, and
(c) absence of CD45.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cancer is melanoma and the CTCs are characterized by one or more of the following characteristics:
(a) diameter of between about 7 and 25 microns, and
(b) presence of one or more markers selected from the group consisting of CD146, Melanin, PAX3d, MLANA, TGFβ2, MCAM, ABCB4, CSPG4, MART-1, MAGE-A3, and GAINAc-T.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer is sarcoma and the CTCs are characterized by one or more of the following characteristics:
(a) diameter of between about 7 and 25 microns, and
(b) presence of vimentin.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cancer is renal cell carcinoma and the CTCs are characterized by one or more of the following characteristics:
(a) diameter of between about 7 and 25 microns, and
(b) presence of one or more markers selected from the group consisting of vimentin, CD10, CK8, CK18, CK19, c-Kit, and E-cadherin.

### Claim 10 (depends on 1)

The method of claim 1, wherein the mitotic cell cycle phase is determined by staining the cells with a nuclear stain and visually determining the cell cycle phase.

### Claim 11 (depends on 1)

The method of claim 1, wherein the mitotic index is calculated by dividing the number of CTCs determined to be in a mitotic cell cycle phase by the number of CTCs determined to be in a non-mitotic cell cycle phase.

### Claim 12 (depends on 1)

The method of claim 1, wherein the population of CTCs are obtained from a biological sample using filtration.

### Claim 13 (depends on 12)

The method of claim 12, wherein the filtration is via a filter comprising a photo-definable dry film.
